Quantum computing ETFs surge 45% as CHIPS Act unlocks $2 billion

The quantum computing trade has shifted from a speculative bet to an identifiable, investable theme, and the three exchange-traded funds that best capture it each take a different angle on the same transition. Defiance Quantum ETF (QTUM) holds a pure-play roster of qubit makers and quantum-adjacent semiconductor companies. ARK Autonomous Technology & Robotics ETF (ARKQ) layers active management over an autonomous-tech mandate that touches the same compute build-out. Global X Robotics & Artificial Intelligence ETF (BOTZ) provides picks-and-shovels exposure through industrial automation and AI hardware.

"Federal capital has validated what the market was already pricing in — that quantum computing is no longer a physics experiment but a procurement line item," said Rachel Kim, an analyst covering AI infrastructure at Edgen. "The $2 billion CHIPS allocation de-risks the modality race and gives investors a concrete timeline to anchor against."

The catalysts are concrete. On May 21, the Department of Commerce announced about $2 billion in CHIPS Act letters of intent to nine quantum companies, including $100 million each for D-Wave, Rigetti, Quantinuum, PsiQuantum, Atom Computing and Infleqtion. That federal capital builds on IBM's error-correction milestones and Google's Willow chip benchmarks, which have shifted the conversation from "will quantum work" to "which modality scales first." Performance has tracked the narrative: QTUM is up 45% year-to-date and 86% over the last 12 months, while ARKQ has returned 25% and BOTZ 11% over the same period.

What matters for investors is that each fund captures a different layer of the same compute transition. QTUM, the only quantum-specific ETF, tracks the BlueStar Quantum Computing and Machine Learning Index with an equal-weight methodology that prevents IBM and Alphabet from dominating the portfolio. That means pure-play names like IonQ, Rigetti and D-Wave contribute meaningfully to returns — for better or worse. The fund's 0.40% expense ratio is competitive for a thematic vehicle this narrow, but the volatility is direct: QTUM has gained roughly 23% in the past month alone.

ARKQ takes a different path. The actively managed fund holds Tesla at about 10% of net assets, followed by Teradyne at roughly 7% and Advanced Micro Devices at about 8%. The semiconductor and testing names matter because qubit systems need classical control electronics, cryogenic test infrastructure and AI orchestration software to operate. Teradyne builds the test equipment, AMD provides the classical compute layer and Palantir handles the data workflows that quantum simulations will eventually plug into. The trade-off is concentration risk: 10 positions account for more than half of the fund's $2.1 billion in assets.

BOTZ offers the broadest exposure. The $3.44 billion fund concentrates in industrial robotics, machine vision and AI compute hardware, with Keyence at roughly 9% of net assets, ABB at about 9%, FANUC near 9% and NVIDIA around 8%. The industrial automation names supply the precision manufacturing equipment that fabricates qubit chips, photonic packages and cryogenic enclosures. BOTZ's five-year return of 19% is a reminder that broad automation exposure does not compound as much as pure thematic plays during a hype cycle, but it also carries less drawdown risk when a single-qubit company misses a milestone.

For investors trying to choose, the decision comes down to which layer of the quantum stack they want to own. QTUM captures the qubit commercialization trade directly, with CHIPS funding announcements and IBM or Google milestones as the primary catalysts. ARKQ fits those who want active management and are comfortable with a concentrated portfolio that touches quantum through semiconductors, defense and AI software rather than through IonQ and Rigetti directly. BOTZ is the structural holding — it benefits regardless of which qubit modality wins, a position that may age well if the commercial timeline stretches past current expectations.

QTUM trades at a price-to-sales ratio that reflects the small pure-plays' early-stage losses — IonQ and Rigetti each reported negative net margins above 2,700% in their most recent fiscal years. But the revenue trajectory is improving: Rigetti's first-quarter 2026 revenue surged 198.9% year-over-year to $4.4 million, driven by commercial deployment of its Cepheus 108-qubit system. The company also signed a CHIPS Act letter of intent for up to $100 million, making the U.S. government a stakeholder in its superconducting architecture. Investors who want all three angles can blend the funds, weighting toward QTUM for thematic intensity and toward BOTZ for diversification across the broader compute transition.

This article is for informational purposes only and does not constitute investment advice.